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ABSTRACT
Basal-cell carcinoma is a commonly occurring
skin malignancy that has the potential to
progress into locally invasive or resistant
disease, as well as spread distantly. Due to
advances in the molecular understanding of
the disease over the last two decades, it has been
discovered that the Hedgehog pathway plays an
important role in the pathogenesis of this
disease and can be exploited as a treatment
target. Several agents that inhibit the Hedgehog
pathway have reached clinical studies and one
drug, vismodegib, has recently been US Food
and Drug Administration (FDA) approved based
on clinical activity and tolerability in patients
with advanced basal-cell carcinoma. This review
will describe the clinical development of
vismodegib, as well as the proper application
of the drug in clinical practice. Other important
clinical questions, such as mechanisms of
resistance to vismodegib and the role of other
Hedgehog pathway inhibitors currently in
development will also be discussed.
Keywords: Basal-cell carcinoma; Hedgehog
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More than 2 million cases of nonmelanoma
skin cancers were diagnosed in 2006 with
approximately 80% of these being basal-cell
carcinoma (BCC) [1]. Fortunately, BCC tumors
rarely spread internally and are generally
curable with local approaches such as surgical
excision, radiotherapy, topical imiquimod, or
photodynamic therapy [2]. However, in some
cases BCC can progress to a point of significant
local invasion such that surgical excision is not
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feasible or removal is associated with excessive
morbidity or disfigurement. Additionally, some
BCC tumors are not amenable to radiotherapy
due to being in sensitive locations, or they can
recur post-radiation therapy making further
localized approaches not possible. Finally,
although very rare, BCC can metastasize to
distant sites of the body, which is considered a
terminal condition. Patients with metastatic
BCC have a median survival of around
8 months [3]. Locally, invasive BCC that is not
amenable to surgical or radiation approaches or
metastatic BCC are termed advanced BCC, and
until recently, limited treatment options were
available for patients with advanced BCC. No
cytotoxic chemotherapy has been approved for
the treatment of advanced BCC; however,
agents such as cisplatin have been used for
patients with metastatic BCC with varied
results [4].
Etiology
Similar to other skin malignancies, the risk of
development of sporadic BCC has been linked
to ultraviolet radiation exposure, skin type,
family history, prior history of skin tumors,
and immunosuppression [5–7]. However, a
variety of hereditary syndromes can result in
an increased risk of developing BCC tumors,
including nevoid BCC syndrome, Bazex–Dupre´–
Christol syndrome, Rombo syndrome, Oley
syndrome, and xeroderma pigmentosum [8].
Nevoid BCC syndrome, which is also known as
Gorlin–Goltz syndrome or simply Gorlin
syndrome, is an autosomal-dominant
condition that results in a varying array of
defects including, but not limited to events
such as macrocephaly, frontal bossing,
congenital cataracts, hypertelorism, palmar
pits, spina bifida, polydactyly, and
hypogonadism [9]. This condition, which was
first described in 1960, is also associated with
the potential for development of numerous
BCC tumors and medulloblastoma. A
landmark finding published in 1996 described
a germline mutation of the patched gene
(PTCH), which is found on chromosome
9q22.3, and accounts for the findings in
Gorlin syndrome [10, 11]. There have been a
variety of types of mutations in the PTCH gene,
which have been described including insertion,
deletion, missense, nonsense, and splice site
mutations [12]. Interestingly, sporadic cases of
BCC can also have mutations in the PTCH or
smoothened (SMO) gene with abnormal
Hedgehog pathway signaling playing a
dominant role in most cases [13–15]. It is
translation of these basic science findings to
the clinic which has resulted in a new
generation of targeted therapeutics for the




The Hedgehog pathway plays a critical role in
embryonic development and is not active in
most adult tissues, with the exception of stem
cells, hair follicles, and skin cells in which the
pathway is important for cell maintenance [16].
Key components of the Hedgehog pathway
were first described in 1980 by Nusslein-
Volhard et al. [17]. Hedgehog pathway
signaling starts with the Hedgehog (Hh) ligand
binding to a 12-pass transmembrane receptor
known as PTCH, which is located in the primary
cilium of the cell (Fig. 1). In 1993, three
mammalian homologs of the Hh ligand were
described, including Sonic Hedgehog (named
after the popular Sega videogame), and also
Indian Hedgehog and Desert Hedgehog (both
named after real hedgehog species) [18, 19]. The
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‘‘Hedgehog’’ moniker was coined based on the
description of Drosophila melanogaster (fruit fly)
larvae, which took on the appearance of the
spiky hedgehog when the gene was mutated.
In the absence of the Hh ligand, the PTCH
receptor acts as a tumor suppressor by inhibiting
the next protein in the pathway known as
Smoothened (Smo), which is a G-protein-coupled
receptor. When the Hh ligand binds to PTCH, the
inhibitory effects on Smo are released allowing
the signal to propagate. Although the
mechanisms following Smo inhibition release
have not been completely elucidated, Smo
activation ultimately results in the release of
inhibition of glioma-associated protein (Gli)
through the suppressor of fused molecule
(Sufu). The Gli family of proteins (Gli-1–3) are
zinc finger transcription factors that are capable
Fig. 1 The Hedgehog pathway in basal-cell carcinoma. In
the majority of normal human cells, the hedgehog pathway
is suppressed (a). The 12-pass transmembrane receptor
Patched (PTCH) inhibits Smoothened (Smo), which
through a series of incompletely elucidated steps, results
in Suppressor of Fused (Sufu) inhibition of Glioma-1/2
(Gli-1/2) transcription factor function. However, in the
presence of Hedgehog ligand (Hh) or mutation of PTCH
or Smo, PTCH suppression of Smo is lifted resulting in
inhibition of Sufu and release of Gli-1/2 transcriptional
activity (b). Vismodegib and other Smo inhibitors block the
Hedgehog pathway by inhibiting Smo resulting in suppres-
sion of Gli-1/2 transcriptional activation (c)
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of activating a number of target genes, which can
result in an oncogenic effect on the cell. Among
the genes that are upregulated through Gli
transcriptional activation are PTCH1 (provides
negative feedback of pathway), Gli-1 (positive
pathway feedback), and other gene pathways that
aid in the survival of the cell, such as angiogenesis
[20, 21], cell cycle regulation [22], and
antiapoptosis pathways [23]. The Hedgehog
pathway also conducts significant crosstalk with
other molecules and pathways including p53,
Wnt, PI3 K/aKT/mTOR, and retinoic acid. These
interactions create a complex network, which
may promote a variety of resistance mechanisms
for drug targeting of this pathway. A variety of
diseases have been linked to abnormal Hedgehog
pathway signaling besides BCC, including
medulloblastoma, hematologic malignancies,
and other solid tumors [24].
Cyclopamine, the first naturally occurring
inhibitor of the Hedgehog pathway, was
isolated from the Veratrum californicum (the
California corn lily) plant [25]. Cyclopamine
was named after its ability to induce cyclopia
and holoprosencephaly in the progeny of
animals that fed on the plant while pregnant,
highlighting the alkaloid’s role in impairing the
Hedgehog pathway in developing embryos.
Cyclopamine was first found to bind to the Smo
receptor resulting in blockade of downstream Hh
signaling pathway transduction [26]. This
discovery has led to a variety of more potent
and selective Smo antagonists, which have been
developed and incorporated into clinical research
for a variety of cancer types, including patients
with advanced BCC.
METHODS
A PubMed search was utilized to retrieve the
data presented in this review article. The search
terms BCC, metastatic basal-cell carcinoma,
smoothened inhibitor, Hedgehog pathway,
vismodegib, LDE-225, and targeted therapy
were used for this search. Additionally,
abstracts from national cancer meetings were
obtained via a similar search on the American
Society of Clinical Oncology (ASCO) website
and the European Society of Medical Oncology
(ESMO) website.
VISMODEGIB (GDC-0449)
Vismodegib (GDC-0449) is a first-in-class, orally
bioavailable inhibitor of Smo. Based on the
efficacy and tolerability results of recent clinical
studies, vismodegib received US Food and Drug
Administration (FDA) approval on January 30,
2012. Table 1 [27–32] summarizes the critical
studies that have explored the use of
vismodegib for BCC.
The first study was published in 2009 by Von
Hoff et al. [27] and described the results of a
dose-escalation phase 1 trial of vismodegib in
patients with metastatic or locally advanced
BCC. In this study, 68 solid tumor patients,
including 33 patients with metastatic or locally
advanced BCC, were treated with three different
doses of drug. The study consisted of two
phases, a dose-escalation phase followed by an
expansion cohort. In the dose escalation phase
of the trial, patients received 150, 270, or
540 mg daily, with each dosing group
including one BCC. Based on pharmacokinetic
studies, 150 mg daily was chosen as the optimal
dose from this first stage of the trial. The second
stage involved expansion cohorts, including 12
non-BCC patients, 20 patients with advanced
BCC (dosing included 150 or 270 mg/day), and
16 patients with solid tumors (10 of which had
advanced BCC). Results of the complete study,
including other solid tumor types, have been
presented elsewhere and demonstrated activity
in medulloblastoma in addition to BCC [31].
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For those with BCC, key inclusion requirements
included histologically confirmed locally
advanced or metastatic BCC considered
refractory to standard therapy, Eastern
Cooperative Oncology Group (ECOG)
performance status 0–2, absence of prolonged
QT interval, and negative pregnancy test for
females. Patients who had radiographically
measurable disease had imaging studies at
baseline and every 8 weeks with responses
measured by Response Evaluation Criteria In
Solid Tumors (RECIST) (version 1.0) criteria.
Of the 33 patients enrolled with BCC, 17
patients received GDC-0449 at a dose of 150 mg
daily, 15 received 270 mg daily, and one patient
received a dose of 540 mg daily. Additionally,
15 patients (45%) had locally advanced BCC
and 18 patients (55%) had metastatic BCC. Prior
treatments, included surgery (n = 28, 85%),
radiation therapy (n = 19, 58%), and systemic
therapy (n = 15, 45%). Of the 18 patients with
metastatic BCC, there were 15 with
radiographically measurable disease, with seven
of these having a partial response ([30%
shrinkage of tumor size). Two additional
patients had partial responses based on imaging
and physical exam. Seven patients had stable
disease and two patients had progressive disease
as their best response. The overall response rate
(ORR) was 50% for metastatic BCC. Of the 15
patients with locally advanced BCC, there were
two complete responses, seven patients with
partial response, four patients with stable
disease, and two patients with progressive
disease as best response. The ORR for locally
advanced BCC was 60%. At the time of study
publication, the median duration of response
was 8.8 months and ongoing. In terms of
toxicities, there were no dose-limiting adverse
effects noted. There was an isolated case of grade
Table 1 Studies evaluating vismodegib for basal-cell carcinoma (BCC)
Trial Design/
population
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150 mg daily or
placebo
Vismodegib cohort: mean 2
new lesions per year;
placebo cohort: mean 29
new lesions/year
32
LaBCC locally advanced BCC, mBCC metastatic BCC, ORR objective response rate, PFS progression-free survival
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4 asymptomatic hyponatremia. Grade 3 events
included fatigue, hyponatremia, weight loss,
dyspnea, muscle spasm, and prolonged QT
interval. Correlative molecular studies in select
patients showed mutations in the PTCH1 gene
in nine of ten specimens analyzed, loss of
heterozygosity of the PTCH1 gene in one
patient’s tumor, SMO-M2 mutations in one
patient, PTCH1 mutations in normal skin of a
patient with basal-cell nevus syndrome, and
elevated Gli-1 mRNA expression in 25 of 26
biopsied tumors. Of the four patients with
progressive disease, one patient was not found
to have Hedgehog pathway signaling, whereas
two of the others analyzed did have signaling
suggesting other more important driving
mutations for these patients.
Pivotal Phase 2 Study of Vismodegib
The findings of the phase 1 trial by Von Hoff
et al., led to exploration of vismodegib (GDC-
0449) in a multicenter, international, two-
cohort phase 2 trial in patients with metastatic
or locally advanced BCC [28]. In this study, 104
patients with locally advanced or metastatic
BCC were enrolled to receive vismodegib
150 mg by mouth daily. The primary endpoint
of the study was objective response rate. There
was no control group or randomization
performed in the study, and the two cohorts
evaluated were divided based on the presence of
metastatic or locally advanced BCC. For the
patients with metastatic BCC, RECIST criteria
(version 1.0) were employed. Independent
review was used to assess radiographs and
photographic images (for locally advanced
patients). For locally advanced BCC patients,
independent pathologic evaluation was
performed to determine whether the response
was partial or complete (absence of residual
BCC in biopsy specimen). Key eligibility
requirements included histologically
confirmed metastatic or locally advanced BCC,
ECOG performance status of 0–2,
radiographically measurable disease (for
metastatic patients), at least one 10 mm or
greater skin lesion (for locally advanced
patients), and surgical or radiotherapeutic
management was inappropriate (locally
advanced patients). Women of childbearing
potential or men with female partners of
childbearing potential were required to use
two methods of contraception. Thirty-three
metastatic BCC patients and 71 patients with
locally advanced BCC were enrolled and
received treatment [28].
Most patients with metastatic BCC had three
or more measurable target lesions (61%) with
the most frequent sites of metastasis being lung
and lymph nodes. Prior treatments for patients
with metastatic disease included surgery (97%),
radiation (58%), and systemic therapy (30%).
The objective response rate for patients with
metastatic BCC was 30% upon independent
review (45% site review). An additional 64% of
metastatic patients had stable disease as best
response on independent review (45% on site
review), and 3% had progressive disease (6% site
review). The median progression-free survival
(PFS) was found to be 9.5 months for the
metastatic cohort with a median duration of
treatment of 10.0 months. In a subsequent
presentation of the updated results of this
study, median overall survival was found to be
24.1 months for patients with metastatic BCC
[29].
Of the patients with locally advanced BCC,
38% were considered to have inoperable
disease, with remainder considered to have
surgically inappropriate due to multiple
recurrences (25%), considerable chance for
deformity or morbidity (51%), or both reasons
(14%). In terms of radiotherapy, 21% had target
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lesions that were refractory to prior radiation,
and 79% had lesions that were considered to be
contraindicated or inappropriate for
radiotherapy. The median objective response
rate was found to be 43% upon independent
review (60% site review). There were 38% of
patients with stable disease (24% site review)
and 13% with progressive disease (10% site
review) as best response. The median PFS for
locally advanced BCC patients was found to be
9.5 months with a median duration of
treatment of 9.7 months. Of the patients who
had biopsy to confirm response, 54% had no
pathologic evidence of disease upon sampling.
Median overall survival for patients with locally
advanced BCC has not been reached [29].
Adverse events from vismodegib in this
study included muscle spasms, alopecia,
dysgeusia, weight loss, fatigue, nausea, loss of
appetite, and diarrhea. There were 13 patients
(12%) who discontinued treatment due to
adverse events, with the most common reason
being muscle spasms. Molecular analysis of
mRNA expression of Gli-1 and PTCH2 were
measured and shown to have similarly high
levels in both the locally advanced and
metastatic cohorts.
An expanded access study of vismodegib has
also been conducted to help further understand
the activity of the agent and allow access of the
drug to locally advanced/metastatic BCC
patients prior to FDA approval [29]. Final
results of the expanded access study were
recently presented at ESMO 2012. Of the 120
patients enrolled, 96 patients were evaluable for
response and showed evidence of clinical
activity with 26 of 57 locally advanced
patients having a response (45.6%, investigator
assessed), and 12 of 39 patients with metastatic
patients having a response (30.4%, investigator
assessed). No patients in the locally advanced
BCC cohort and 7.7% of the metastatic BCC
cohort experienced progressive disease as best
overall response. Side effects were similar to that
seen in the pivotal phase 2 trial and included
muscle spasms, dysgeusia, alopecia, nausea,
weight loss, fatigue, and diarrhea [29].
Use of Vismodegib in Basal-Cell Nevus
Syndrome
Vismodegib has also been prospectively
evaluated in patients with basal-cell nevus
syndrome (Gorlin syndrome) [30]. In a
randomized, double-blind, placebo-controlled
trial, 42 patients with basal-cell nevus
syndrome were enrolled to determine the anti-
BCC efficacy. The primary endpoint of the study
was the comparative rate of appearance of new
surgically resectable BCC lesions between the
treatment and placebo arms. Surgically
resectable BCC lesions were defined as being
C3 mm on the nose or around the eyes, C5 mm
on other areas of the face, and C9 mm on the
trunk or limbs. Other endpoints included an
evaluation of the frequency of smaller BCC
lesions, reduction in the size of existing
surgically resectable lesions, duration of the
effect of vismodegib after discontinuation, and
safety. Additionally, evaluation of changes in
Hedgehog pathway gene expression was
measured by quantitative polymerase chain
reaction (PCR) analysis of Gli-1 at baseline and
at 1 month after start of therapy. Eligibility for
the trial required a clinical diagnosis of basal-cell
nevus syndrome as defined by at least two major
criteria and at least ten surgically eligible BCC
lesions at study entry or that were removed
during the 2 years prior to enrollment.
Treatment included vismodegib at 150 mg by
mouth daily or matching placebo for up to
18 months or until intolerable adverse effects or
clinically worsened disease. Clinically worsening
disease was defined as[60 new surgically eligible
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BCCs or a doubling of the longest diameter of
existing or new BCC lesions. Patients could have
surgical resection of BCC lesions if it was decided
necessary by the primary dermatologist [30].
Of the 42 patients enrolled, 41 patients were
randomized in a 2:1 fashion and received
treatment. The two arms were well balanced
based on age, weight, and number of BCC lesions
at baseline (44 lesions per patient in the
vismodegib arm vs. 37 lesions per patient in the
placebo arm, P = 0.79). Patients in the vismodegib
arm were found to have a significantly reduced
number of new surgically eligible BCC lesions
compared to the placebo group (mean of two new
lesions per year for vismodegib compared to 29
new lesions per year for the placebo group,
P\0.001). Additionally, vismodegib was shown
to reduce the mean size of existing BCC lesions
(longest diameter) compared to placebo (–65% for
vismodegib vs. –11% for placebo, P = 0.003).
Vismodegib-treated patients also had fewer
surgical resections of BCC lesions compared to
placebo (0.31surgeriesperpatientcomparedto4.4
for placebo, P\0.001). Tumor responses were
seen in all tumors treated with vismodegib with
some near-complete responses. At the time of the
report, 54% of patients had discontinued
treatment with vismodegib due to adverse
events. Common side-effects from vismodegib
included dysgeusia, muscle cramps, hair loss, and
weight loss [30].
Histologic and molecular studies confirmed
the anti-BCC effect and molecular pathway
targeting of vismodegib. In lesions that
appeared clinically resolved, residual BCC
tumor cells were seen in only 17% of biopsied
specimens (n = 1 of six). Evaluation of Gli-1
mRNA expression by PCR demonstrated a 90%
decrease compared to pre-treatment biopsy
specimens (P\0.001). Reduction in Ki67
expression was also seen, but there was no
change in apoptosis (as measured by cleaved
caspase 3). In patients who stopped vismodegib
and had at least 3 months post-treatment follow-
up (n = 4), it took several months (*18) for the
sum of the longest diameter of existing lesions to
reach their baseline size. Additionally, the rate of
new lesions in vismodegib-receiving patients
after discontinuation of drug was less than that
for those on placebo (0.69 new per month
compared to 2.4 new per month for placebo) [30].
This study has highlighted several important
points regarding the treatment of patients with
basal-cell nevus syndrome with a Smo inhibitor.
Although active treatment with vismodegib was
able to control the rate of new lesions and
decrease the size of existing lesions, the
treatment was intolerable for many patients,
making long-term use challenging. Although
the rate of new lesions after discontinuation of
vismodegib was still lower than those in the
placebo arm, the effect was much less
prominent than when these patients were on
active treatment. These findings confirm an
inhibitory effect of Smo blockade on BCC
tumor cell growth over time; however, few
patients are likely to have a long-term benefit
due to either primary resistance which develops
in a small population of tumor cells or the
toxicity ceiling of the drug prevents prolonged
use and thus incomplete tumor cell kill. As
Gorlin syndrome represents a lifelong disease
with continuous potential for the development
of BCC tumors, the ideal treatment would be
one that is effective and tolerable enough for
continued use (perhaps a topical therapy).
LDE225
Via cell-based high-throughput screening,
LDE225 was identified as a selective, potent
inhibitor of Smo, which is currently in clinical
development for BCC and other cancer types
[31]. It has been evaluated in a phase 1
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dose-escalation study, which was reported at
ASCO in 2010 [32]. In this study, patients with
advanced solid tumors were treated with varied
doses of LDE225 (100, 200, 400, and 800 mg)
with the primary goal of determining the
maximally tolerated dose (MTD). At the time
of the presentation, 25 patients had been
treated with no dose-limiting toxicities noted.
Common side-effects included fatigue, nausea,
vomiting, anorexia, muscle cramps, and
dysgeusia. Additionally, at the time of the
report one patient with medulloblastoma had
obtained an objective response, whereas five
other patients had at least stable disease for
4 months (including one BCC patient). A
reduction in Gli-1 mRNA expression was noted
in skin samples of patients with the level of
reduction correlating with dose of LDE225.
LDE225 has subsequently entered testing in
a phase 2 randomized trial for patients with
locally advanced or metastatic BCC in 2011,
which is currently ongoing. In this study,
patients are randomized to one of two
different doses of LDE225. The primary
endpoint of the study is objective response
rate by 6 months with secondary endpoints
including duration of response, PFS, and
safety. Additionally, a trial of LDE225 in
patients who have progressed on another Smo-
inhibitor (e.g., vismodegib) is currently being
conducted, which will shed light on the role of
cross-resistance with these inhibitors
(ClinicalTrials.gov number: NCT01529450).
LDE225 has also been evaluated in the
management of nevoid BCC syndrome. In this
trial, eight patients were treated with 0.75%
LDE225 and vehicle [33]. Lesions on each
patient were randomized to the active LDE225
cream or vehicle only. There were a total of 27
lesions treated with either the LDE225 cream or
vehicle twice daily for 4 weeks. Fourteen lesions
received vehicle whereas 13 lesions received
LDE225 cream. There were clinical responses in
all lesions treated with LDE225 except one.
Clinical responses included three complete
clinical responses and nine partial responses.
Clinical response was seen in only one of the 14
lesions treated with the vehicle. Both the
LDE225 cream and vehicle were well tolerated
with no reported skin toxicities. Systemic
absorption of LDE225 was below the limit of
detection in 50% of the patients with the
highest concentration noted in the other four
patients being 0.11 ng/mL. Correlative analysis
on biopsied tumors after LDE225 topical
treatment revealed downregulation of
Hedgehog pathway gene targets, such as Gli-1,
Gli-2, PTCH1, and PTCH2. Certainly, for
patients with numerous localized BCCs, such
as in nevoid BCC syndrome, the use of topical
LDE225 appears to be a rational approach as it




A variety of other agents that inhibit Smo are in
clinical development. These agents have been
evaluated, or are currently being evaluated, in
phase 1 clinical studies. These include BMS-
833923, which has been described in a phase 1
clinical trial in advanced solid tumors [34]. This
study was reported in 2010 at ASCO, and at the
time of the report 18 patients had been treated
with BMS-833923 at doses ranging from 30 to
240 mg. One patient with Gorlin syndrome
who was treated with the 240 mg dose had a
confirmed partial response, and another patient
with medulloblastoma had stable disease lasting
for more than 11 months. Further updates from
this trial are expected. Currently, trials with
BMS-833923 are ongoing in small cell lung
cancer, chronic myeloid leukemia (CML),
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multiple myeloma, and gastrointestinal
malignancies. Several other Smo inhibitors are
being evaluated in first-in-human clinical
studies. This includes TAK-441 (Millennium,
Cambridge, MA, USA; ClinicalTrials.gov
number: NCT01204073) and LEQ506
(Novartis, Basel, Switzerland; ClinicalTrials.gov
number: NCT01106508), which are also in early
phase studies with advanced solid tumors.
MECHANISMS OF RESISTANCE
TO SMO INHIBITION
Although treatment of BCC with vismodegib
and similar agents has resulted in dramatic
responses, resistance to Smo inhibition occurs
resulting in new tumor development or growth
of previously responding tumors. A recent
analysis into the mechanism of resistance to
vismodegib has recently shed light into the
complex nature of this process [35]. In a patient
with medulloblastoma with a known PTCH
mutation, the initial response to vismodegib
was seen with subsequent progression of disease
[36]. Comparison of before treatment tumor
samples and samples obtained from a
vismodegib-resistant tumor demonstrated a
novel finding. The pre-existing PTCH
mutation found in the pre-treatment tumor
was still present in the resistant tumor;
however, a new mutation in SMO (D473) was
seen. Similar to alterations in BCR–ABL, which
confer resistance of CML cells to imatinib, this
SMO-D473 mutation was found to confer
resistance to vismodegib. Further evaluation
implicated that this particular mutation
affected vismodegib binding to Smo. A panel
evaluating other point mutations in this
particular location uncovered potential
oncogenic properties with autoactivation of
Smo signaling [37]. Evaluation of other Smo
inhibiting agents, demonstrated several
potential candidates that could inhibit wild-
type Smo and this new D473 mutation. Thus
development of next-generation Smo
inhibitors, which have a broader Smo
inhibitory profile, could be a key to unlocking
more durable benefits. Additionally, inhibition
of downstream molecules, such as Gli, could
have benefits to patients with Smo-inhibitor
refractory tumors or as vertical inhibition
combination strategies with current Smo
inhibitors. Several Gli-inhibitor molecules
have been discovered, including GANT 58 and
GANT 61; however, agents such as these have
yet to be evaluated in clinical studies [38].
Finally, other pathways play important roles via
either downstream Hedgehog pathway
regulation or Hedgehog pathway crosstalk.
Some BCC cell lines that demonstrate Smo-
inhibitor resistance rely on the PI3 K-Akt
pathway. Coinhibition of Smo and PI3 kinase
in these Smo-inhibitor resistant cell lines has
demonstrated subsequent tumor responsiveness
to treatment, implicating possible horizontal
pathway inhibition strategies, which could be
employed clinically [39]. Although, the
mechanisms of resistance to Smo inhibitors
remains incompletely evaluated, further
information is likely to be forthcoming as
ongoing trials are collecting tumor samples
upon progression, which should further guide
future treatment development strategies.
PRACTICAL CONSIDERATIONS
FOR THE USE OF VISMODEGIB
Vismodegib represents a first-in-class
medication for use in patients with locally
advanced or metastatic BCC. As with any new
drug, there is a learning curve to overcome in
the community. Before the clinical
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development and approval of vismodegib, there
was little thought of using systemic therapy in
these patients as chemotherapy has little
activity. Advanced BCC patients are cared for
by a wide range of disciplines including
dermatologists, Mohs surgeons, plastic
surgeons, otolaryngologists, and radiation
oncologists. With the approval of vismodegib,
medical oncologists now have a larger role to
play. Common questions include: Who is the
appropriate patient to receive this agent? How
long should treatment with vismodegib be
continued in someone with a complete
response? What is done for patients who do
not tolerate the medication? What do we do
upon progression? Certainly, some of these
questions can be answered with evidence-
based support; however, others remain the
focus of ongoing and future research.
Practical Management of Locally
Advanced BCC
Based on the author’s current knowledge,
eligible patients can be broken down into two
categories: locally advanced BCC and metastatic
BCC. Although metastatic BCC is easy to pick
out as these patients have clinically apparent
metastatic deposits on radiographs, the locally
advanced BCC patients are a little trickier. Some
of these locally advanced BCC patients present
to the treating physician after years of neglect
with their tumors slowly growing to involve
deep structures. This happens for a variety of
reasons, including patient denial or lack of
access to medical care due to psychiatric
disorders, financial constraints, or social
isolation. Other situations in which this occurs
are due to patient predisposition with risk
factors, such as extensive sun exposure, Gorlin
syndrome, immunosuppression, or
development of lesions in very sensitive areas.
Although the reason for development of
locally advanced BCC varies, the identification
of these patients can be guided from an
evidence-based approach (Table 2). The
definition of the locally advanced BCC patient
eligible for the pivotal vismodegib study can be
simplified to those with (1) recurrent BCC after
surgery or radiotherapy, or (2) patients that
were deemed ineligible for surgery and
radiotherapy. There are many scenarios that
can lead to one of these two classifications and
these are outlined in Table 1. Although some
BCCs that are locally recurrent after surgery can
proceed to radiotherapy as a salvage option,
location of the BCC matters. BCC lesions
around the eyes or other sensitive areas are
common and radiotherapy can definitely be
more challenging or impossible for these
locations of involvement. In the pivotal study,
patients who had lesions that had recurred after
at least two attempts at surgical resection were
included. Additionally, patients who were not
deemed surgical candidates because surgical
resection would result in significant deformity
or morbidity were included. Also, in clinical
practice, some patients may be deemed
ineligible for surgery or radiotherapy due to a
high number of lesions. These patients may be
Gorlin syndrome patients or they may be
patients with extensive UV exposure or
immunosuppression who have numerous
lesions, making surgery or radiotherapy
impractical. Finally, other patients to consider
for vismodegib with localized disease include
patients with comorbid conditions that
preclude extensive surgical resection and
general anesthesia and who are also not
candidates for radiotherapy.
Another practical question is the use of
vismodegib in the preoperative setting to
attempt to convert an unresectable or difficult
to resect lesion into one that can be managed
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easier. Although this would be considered a
common-sense application of this medication,
which has great potential to reduce lesion sizes,
this approach needs to be evaluated in clinical
studies. Currently, trials evaluating the
preoperative use of vismodegib in patients
with BCC are ongoing (ClinicalTrials.gov
numbers: NCT01543581, NCT01201915).
Although some patients who are initiated on
vismodegib have a complete response, a more
typical outcome is partial response. The duration
of this response varies but for the average patient,
the BCC tumor does recur and management after
vismodegib remains an important unanswered
question. Certainly, patients may have the
option of receiving surgical therapy or
radiotherapy if the treatment with vismodegib
resulted in a response that changed the feasibility
of further local options. For patients who still
cannot have further therapy, identification of a
clinical trial is crucial to advancing our
understanding of how to manage these patients.
Currently, a trial of LDE225 in patients previously
treated with vismodegib or other Smo inhibitors
is ongoing (ClinicalTrials.gov number:
NCT01529450). Also for patients with multiple
localized BCCs, such as in Gorlin syndrome, use
of vismodegib may be required for a long period
of time raising the question of intermittent
dosing to either reduce the chance of BCC
resistance as well as to improve tolerability of
the agent. To further understand the feasibility of
this approach, an ongoing trial exploring
intermittent dosing is being performed with
vismodegib compared to photodynamic therapy
(ClinicalTrials.gov number: NCT01556009).
Practical Management of Patients
with Metastatic BCC
As previously stated, these patients are
fortunately not as common as and are much
easier to identify than those with locally
advanced BCC. It is important for patients
with locally advanced BCC to have imaging
examinations using computed tomography
(CT) or positron-emission tomography (PET)
to rule out metastatic disease. Patients with
metastatic BCC can have sites of involvement
including lung, liver, and bone, so the
examination needs to encompass these areas.
Although patients with oligometastatic disease
can be considered for metastatectomy or
stereotactic radiosurgery, patients with more
extensive disease or surgically unfit patients
should be considered for systemic therapy with
vismodegib or referred for clinical trial. The
treatment goals for these patients are typically
different than those with locally advanced
disease. As metastatic BCC is a terminal
Table 2 Identiﬁcation of locally advanced basal-cell carcinoma (BCC) patients who are appropriate for vismodegib use
Potential reasons to need systemic therapy for BCC
Recurrent disease despite two or more surgical resections
Surgical resection not possible due to inability to completely resect
Resection or radiation would result in too much disﬁgurement or morbidity
Too many lesions to resect or radiate (e.g., numerous sporadic lesions, Gorlin syndrome, immunosuppression, etc.)
Patient is not an operable candidate due to signiﬁcant comorbidities
Recurrence after radiotherapy
Radiation not possible due to close proximity of adjacent organs or structures
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condition, certainly quality of life plays a large
role in their goals of care. Although vismodegib
has been shown to result in an average survival
of approximately 2 years, vismodegib can be
difficult for some patients to tolerate. Therefore,
short treatment breaks could be employed to
help the patient maintain their therapy and
response for a longer period of time.
FUTURE DIRECTIONS
The introduction of selective, potent inhibitors of
the Hedgehog pathway has led to improved
outcomes for patients with advanced BCC who
previously had limited systemic treatment
options. Vismodegib represents a first-in-class
Smo inhibitor, which has shown prominent
clinical activity in phase 2 trials for patients with
advanced BCC and Gorlin syndrome.
Unfortunately, most patients treated with this
drug eventually have disease progression. This is
anticipated for other Smo inhibitors in
development as well. Therefore, it is critical that
further research to help our understanding of Smo
inhibitor resistance be performed. Many of the
trials that are ongoing are actively collecting
samples from progressing lesions for molecular
analysis. It is anticipated that more than one
mechanism of resistance will be identified. Early
evaluation of one patient who has progressed on
vismodegibhas revealed thatmutation intheSmo
molecule can occur, which interferes with
vismodegib binding. This mutation is quite
similar to the mutations noted in BCR–ABL,
which develop in response to exposure to
imatinib. This finding opens the door for the
evaluation of agents that bind to both wild-type
and mutant SMO as a means of overcoming
vismodegib resistance. Additionally, agents that
target downstream molecules in the Hedgehog
pathway, such as Gli or other pathways, which
contribute to Hedgehog pathway inhibitor
resistance, such as the PI3kinase pathway are
also candidates for overcoming resistance.
Certainly, these are areas that need to be further
explored as new agents that have similar activities
are introduced. Finally, it is important to evaluate
these agents earlier in the disease process as
potential adjuvant or neoadjuvant adjuncts to
traditional approaches, which may result in better
outcomes and hopefully prevent the devastating
occurrences of locally advanced and metastatic
forms of BCC.
CONCLUSION
The identification of the Hedgehog pathway’s
role in BCC, as well as drugs that are able to
target this pathway, has led to a critical proof-
of-concept translation of these agents into the
clinical management of advanced BCC. The
first-in-class Smo inhibitor, vismodegib, has
given the clinician an important tool in
treating patients with this devastating disease.
It is critically important that physicians
understand when and how to use this novel
agent in the management of these patients.
Other agents that work similarly to vismodegib
are in development and are expected to expand
the clinical options for these patients even
further. Research into mechanisms of
resistance of Smo inhibitors, identification of
other relevant molecular targets and an
understanding of the use of Hedgehog
pathway inhibitors in earlier stage disease
remains a crucial next step to improving
outcomes for patients BCC.
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